These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 10420057)

  • 1. [Guidelines for estrogen and gestagen replacement in the climacteric and postmenopause. The 21st work meeting of the Zurich Discussion Group, November, 1998].
    Birkhäuser M; Braendle W; Breckwoldt M; Keller PJ; Kuhl H; Runnebaum B
    Gynakol Geburtshilfliche Rundsch; 1999; 39(3):133-5. PubMed ID: 10420057
    [No Abstract]   [Full Text] [Related]  

  • 2. [Recommendations for estrogen and progestin replacement therapy in climacteric and postmenopause. 31. Professional Meeting of the Zurich Discussion Circle, October 2003].
    Birkhäuser M; Braendle W; Keller PJ; Kiesel L; Kuhl H; Neulen J
    Gynakol Geburtshilfliche Rundsch; 2004 Oct; 44(4):258-64. PubMed ID: 15459525
    [No Abstract]   [Full Text] [Related]  

  • 3. [Recommendations for substitution with estrogens and progesterones in climacteric and in postmenopause. 8th Professional Meeting of the Zurich Discussion Group, November 1992].
    Bettendorf G; Breckwoldt M; Keller PJ; Kuhl H; Runnebaum B; Teichmann AT
    Gynakol Geburtshilfliche Rundsch; 1993; 33(1):39-40. PubMed ID: 8471884
    [No Abstract]   [Full Text] [Related]  

  • 4. [Recommendations for replacement of estrogens and progestins in climacteric and in postmenopause. 25. Arbeitstreffen des "Zürcher Gesprächskreises", November 2000].
    Birkhäuser M; Braendle W; Breckwoldt M; Keller PJ; Kuhl H; Runnebaum B
    Gynakol Geburtshilfliche Rundsch; 2001; 41(1):12-5. PubMed ID: 11423732
    [No Abstract]   [Full Text] [Related]  

  • 5. Risk of breast cancer among users of estrogen plus progestogen and unopposed estrogen: is the likelihood of bias symmetrical?
    Shapiro S
    Climacteric; 2015 Jun; 18(3):333-5. PubMed ID: 25651904
    [No Abstract]   [Full Text] [Related]  

  • 6. Hormone replacement therapy: estrogen after menopause.
    Gibaldi M
    Pharmacotherapy; 1996; 16(3):366-75. PubMed ID: 8726594
    [No Abstract]   [Full Text] [Related]  

  • 7. [Substitution therapy with estrogens and gestagens].
    Kuhl H
    Dtsch Med Wochenschr; 1995 May; 120(21):765-8. PubMed ID: 7781501
    [No Abstract]   [Full Text] [Related]  

  • 8. [Recommendations for estrogen and progesterone replacement in climacteric and postmenopause. 33. Workshop of the "Zurich Discussion Circle", October 2004].
    Birkhäuser M; Braendle W; Keller PJ; Kiesel L; Kuhl H; Neulen J
    Gynakol Geburtshilfliche Rundsch; 2006; 46(1-2):53-7. PubMed ID: 16452821
    [No Abstract]   [Full Text] [Related]  

  • 9. Landmark hormone replacement therapy study stopped after finding more harms than benefits.
    Rollins G
    Rep Med Guidel Outcomes Res; 2002 Aug; 13(15):5-7. PubMed ID: 12553323
    [No Abstract]   [Full Text] [Related]  

  • 10. [Hormone replacement therapy of menopause in women with vascular risk factors].
    Charbonnel B
    Diabete Metab; 1993; 19(4):387-90. PubMed ID: 8293865
    [No Abstract]   [Full Text] [Related]  

  • 11. [Increased risk of breast cancer following hormone replacement therapy during climacteric. 3 440 extra cases might have been caused by the treatment in Sweden during the 1990s].
    Magnusson C; Reeves G
    Lakartidningen; 2005 Apr 18-24; 102(16):1228-30. PubMed ID: 15921095
    [No Abstract]   [Full Text] [Related]  

  • 12. Estrogen and progestogen therapy in postmenopausal women.
    Practice Committee of the American Society for Reproductive Medicine
    Fertil Steril; 2006 Nov; 86(5 Suppl 1):S75-88. PubMed ID: 17055850
    [No Abstract]   [Full Text] [Related]  

  • 13. [New SBU-report on estrogen replacement therapy in climacteric. Moderate risk of breast cancer after long-term use].
    Lakartidningen; 2002 Jul; 99(28-29):3031-4. PubMed ID: 12170514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Basic principles of hormone replacement therapy in the postmenopause].
    Dören M
    Ther Umsch; 2000 Oct; 57(10):628-34. PubMed ID: 11081374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen replacement therapy and risk of ovarian cancer.
    Noller KL
    JAMA; 2002 Jul; 288(3):368-9. PubMed ID: 12117404
    [No Abstract]   [Full Text] [Related]  

  • 16. Postmenopausal hormone replacement therapy: does the progestin make a difference?
    Fylstra DL
    J S C Med Assoc; 2002 Feb; 98(1):12-9. PubMed ID: 11859600
    [No Abstract]   [Full Text] [Related]  

  • 17. [Gestagen supplementation to estrogen therapy in climacteric].
    Iversen OE
    Tidsskr Nor Laegeforen; 2001 Jan; 121(1):82-3. PubMed ID: 12013622
    [No Abstract]   [Full Text] [Related]  

  • 18. [Hormone therapy and risk for venous thromboembolism in postmenopausal women].
    Lacut K; Oger E
    Rev Prat; 2005 Feb; 55(4):389-92. PubMed ID: 15828617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progestins and potassium.
    Rosendorff C
    Am J Hypertens; 2005 Jun; 18(6):741-3. PubMed ID: 15925728
    [No Abstract]   [Full Text] [Related]  

  • 20. [Postmenopause and estrogen substitution].
    Jaszmann LJ
    Tijdschr Ziekenverpl; 1978 Sep; 31(18):822-9. PubMed ID: 250310
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.